Objective The efficacy of lamivudine for fulminant hepatitis B has been reported in Europe and West Asia. However, in 
Introduction

Worldwide, hepatitis B virus infection is one of the most frequent causes of fulminant hepatic failure. It has been reported that fulminant hepatitis B occurs in approximately 1% of patients with acute disease and carries a mortality rate of up to 80% (1-3). Liver transplantation has been the only established treatment for fulminant hepatitis B.
Recently, the safety and efficacy of lamivudine treatment for patients with severe acute or fulminant hepatitis B has been reported (4) (5) (6) (7) . Tillmann et al (6) (8, 9) . Genotypes affect clinical features of acute hepatitis B virus infection (10, 11 (2, 13) . Recently, we reported the importance of systemic inflammatory response syndrome as a prognostic factor for fulminant hepatic failure (14) .
reported that lamivudine treatment led to fast recovery with the potential to prevent liver failure and liver transplantation when administered early enough. On the other hand, Kumar et al (7) reported that, though lamivudine significantly decreased hepatitis B virus DNA levels in patients with acute hepatitis B, it did not produce significant biochemical and clinical improvement compared to that in patients receiving a placebo. Thus, it has been controversial whether lamivudine treatment improves the survival of severe acute or fulminant hepatitis B. Furthermore, in these previous reports, the number of patients with hepatic coma was limited, and most of the study populations were infected with hepatitis B virus genotype D (4-7). The hepatitis B virus has been classified into eight genotypes (A-H), and clinical differences between genotypes have been reported
In this study, we tried to clarify the prognostic factors and the efficacy of lamivudine treatment for Japanese patients with fulminant hepatitis B. (Fig. 1) .
Patients and Methods
Patients
Results
Patient selection
Comparison between patients treated and not treated with lamivudine
There were no differences in clinical features at the time of diagnosis of fulminant hepatitis B between patients treated with and without lamivudine (Table 1).
Prognostic factors associated with fatal outcomes of 33 patients with fulminant hepatitis B
Using a univariate Cox proportional hazard model, age (!45 years), systemic inflammatory response syndrome, and non-administration of lamivudine were associated with fatal outcomes. A tendency for a higher ratio of total to direct bilirubin was observed in patients with a poor outcome. The type of disease onset, hepatic coma grade, total bilirubin level, and prothrombin activity were not associated with fatal outcomes (
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The importance of age as a prognostic factor for fulminant hepatitis B has been reported previously (2, 13, 20 
